GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
== Awards and honours == 1923: Nobel Prize in Physiology or Medicine for the discovery of insulin – shared with John Macleod 1923: John Scott Medal of the Franklin Institute 1927: Cameron Prize for Therapeutics of the University of Edinburgh 1931: Flavelle Medal of the Royal Society of Canada 1935: Fellowship of the Royal Society Prior to the award of the Nobel Prize in Physiology or Medicine for 1923—which he shared with Macleod—he received the Reeve Prize of the University of Toronto (1922). In 1923, the Canadian Parliament granted him a Life Annuity of $7,500. Following the Banting's receipt of the Cameron Prize for Therapeutics of the University of Edinburgh in 1927, Banting gave the 1928 Cameron Lecture in Edinburgh. He was a member of numerous medical academies and societies in Canada and abroad, including the British and American Physiological Societies, and the American Pharmacological Society. In 1934, he was knighted as a Knight Commander of the Order of the British Empire (KBE) by King George V and became an active vice-president of the Diabetic Association (now Diabetes UK). In May 1935 he was elected a Fellow of the Royal Society. In 2004, Banting was inducted into the National Inventors Hall of Fame.
Although no high-resolution model of actin's filamentous form currently exists, in 2008 Sawaya's team were able to produce a more exact model of its structure based on multiple crystals of actin dimers that bind in different places. This model has subsequently been further refined by Sawaya and Lorenz. Other approaches such as the use of cryo-electron microscopy and synchrotron radiation have recently allowed increasing resolution and better understanding of the nature of the interactions and conformational changes implicated in the formation of actin filaments.
Several Latin American and Caribbean countries have, at times, faced allegation governments involvement in the illegal drug trade the 1970s and 1980s.In 1978 and 1980, so called "cocaine coups" in Honduras and Bolivia brought such governments to power that were linked to drug trafficking networks (see illegal drug trade in Honduras and illegal drug trade in Bolivia). In Panama, Manuel Noriega, a long-term drug trafficker, served as a head of military from 1983 to 1989, during which he maintained ties with the CIA. The Colombian parapolitics scandal revealed links between parts of the Colombian establishment and the United Self-Defense Forces of Colombia (AUC), a paramilitary group responsible for killing tens of thousands of Colombian civilians, which controls over 75% of the Colombian cocaine trade. The illegal drug trade in Peru was until 2000 shaped by Vladimiro Montesinos's involvement; he had been head of the country's intelligence service since 1990. In 2010 it was alleged that the Mexican Sinaloa cartel had used bribery to co-opt the federal government and focus the government's anti-drug efforts on its competitors. According to Peter Dale Scott, "The Guadalajara Cartel, Mexico's most powerful drug-trafficking network in the early 1980s, prospered largely because it enjoyed the protection of the DFS, under its chief Miguel Nazar Haro, a CIA asset." Now, in the 21st century, there are still major issues with government corruption in Latin America.
Sources: en.wikipedia.org
=== Artificial limbs === NASA's continued funding, coupled with its collective innovations in robotics and shock-absorption/comfort materials are inspiring and enabling the private sector to create new and better solutions for animal and human prostheses. Advancements such as Environmental Robots Inc.'s development of artificial muscle systems with robotic sensing and actuation capabilities for use in NASA space robotic and extravehicular activities are being adapted in order to create more functionally dynamic artificial limbs. Additionally, other private-sector adaptations of NASA's memory foam technology have brought about custom-moldable materials offering the natural look and feel of flesh, as well as preventing friction between the skin and the prosthesis, and heat/moisture buildup.
Asia and Oceania: Under the 1950 Indo-Nepal Treaty of Peace and Friendship, India and Nepal maintain an arrangement similar to the CTA and the Union State. Indians and Nepalis are not subject to any migration controls in each other's countries, and there are few controls on land travel by citizens across the border. India and Bhutan also have a similar programme in place. The border between Jaigaon, in the Indian state of West Bengal, and the city of Phuentsholing is essentially open, and although there are internal checkpoints, Indians (as outlined under the Visa policy of Bhutan are allowed to proceed throughout Bhutan with a voter's ID or an identity slip from the Indian consulate in Phuentsholing. Similarly, Bhutanese passport holders enjoy free movement in India. Thailand and Cambodia: Whilst not as liberal as the policies concerning the Indo-Nepalese and Indo-Bhutanese borders, Thailand and Cambodia have begun issuing combined visas to certain categories of tourists applying at specific Thai or Cambodian embassies and consulates, enabling freer border crossings between the two countries. The policy is currently in force for nationals of America and several European (primarily EU, EEA, and GCC) and Oceanian countries as well as for Indian and Chinese nationals residing in Singapore.
== Further reading == Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. (2021). Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC).
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.